Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

In the wake of Popovich's role change in San Antonio, a funny clip of one of his on-court interactions with NBA great Shaquille O'Neal has resurfaced. Popovich had just beaten Shaq and the Phoenix ...

EPS: US$0.52 (down from US$0.55 in 1Q 2024). We've discovered 3 warning signs about Pfizer. View them for free. Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) exceeded analyst ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Pfizer Inc (NYSE:PFE) kicks off its Q1 report before U.S. markets open on Tuesday, and investors are bracing for a bit of a rough patch. Wall Street models call for adjusted EPS of $0.69, down ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...